The White House re­view of drug prices: Don't hate the play­er — hate the game

For­eign na­tions are spong­ing off Amer­i­can in­vest­ment in­to phar­ma­ceu­ti­cal R&D and tak­ing ad­van­tage of by US pa­tients by sys­tem­at­i­cal­ly un­der­pay­ing for drugs, a new study by the White House has con­clud­ed.

Surg­ing drug prices in the Unit­ed States are a thorny yet rare bi­par­ti­san is­sue as an­oth­er pres­i­den­tial elec­tion beck­ons. While Pres­i­dent Trump strug­gles to make good on his promise to low­er drug prices, the bio­phar­ma in­dus­try, which has long thrived in its lais­sez-faire ecosys­tem, has per­sis­tent­ly ar­gued that gov­ern­ment in­ter­ven­tion will sti­fle in­no­va­tion.

Mean­while, US law­mak­ers left, right and cen­ter have ar­gued drug prices in the Unit­ed States are too high — and the in­dus­try holds the crown for the least fa­vored sec­tor by Amer­i­cans, falling be­hind the fed­er­al gov­ern­ment it­self. In De­cem­ber, the HHS opened the door to a pol­i­cy that al­lows for the lim­it­ed im­por­ta­tion of drugs from Cana­da.

This new White House analy­sis, how­ev­er, sug­gests that US drug prices aren’t un­rea­son­able — its that for­eign gov­ern­ments aren’t pay­ing enough for Amer­i­can phar­ma­ceu­ti­cal break­throughs.

This new study — con­duct­ed by the Coun­cil of Eco­nom­ic Ad­vis­ers (a White House group tasked with of­fer­ing the US pres­i­dent ad­vice on eco­nom­ic pol­i­cy) — com­pared the prices of 200 top-sell­ing brand­ed drugs in the Unit­ed States against 15 de­vel­oped coun­tries. Eu­ro­pean coun­tries went from pay­ing about half (51%) of US prices for many best­selling drugs in 2003 to about a third (32%) by 2017, the re­port found, not­ing that gov­ern­ments abroad ne­go­ti­ate drug prices on be­half of their cit­i­zens and there­by ar­ti­fi­cial­ly de­press prices.

“These prac­tices abroad dis­pro­por­tion­ate­ly cost U.S. pa­tients and tax­pay­ers be­cause they pre­vent the Unit­ed States from un­der­tak­ing do­mes­tic poli­cies to low­er drug prices with­out slow­ing down the pace at which new and bet­ter prod­ucts en­ter the mar­ket,” the re­searchers wrote.

“We find that if free-rid­ing abroad was re­duced and for­eign rel­a­tive drug prices re­flect­ed rel­a­tive GDP per capi­ta, to­tal in­no­va­tor rev­enues from those coun­tries would have been $194 bil­lion high­er in 2017, rais­ing glob­al rev­enues by 42 per­cent. Re­duc­ing for­eign price con­trols would in­crease prof­its and in­no­va­tion, there­by lead­ing to greater com­pe­ti­tion and low­er prices for U.S. pa­tients.”

For in­stance, Cana­da paid 35% of US prices in 2017 — even though its GDP per capi­ta is 78% of the Unit­ed States. If Cana­da were to shoul­der a pro­por­tion­ate cost — it would have paid $27.2 bil­lion in­stead of the ac­tu­al $12.2 bil­lion it part­ed with that year, CEA re­searchers claimed.

In oth­er words, the White House is sug­gest­ing its im­po­tence in im­ple­ment­ing drug price con­trols is linked to for­eign gov­ern­ments not pay­ing their fair share for ben­e­fit­ting from Amer­i­can in­vest­ment in­to phar­ma­ceu­ti­cal R&D.

Crit­ics of that ar­gu­ment will be quick to note that drug prices in the Unit­ed States — a frac­tured sys­tem of health care that runs on pub­lic and pri­vate in­sur­ance, fur­ther com­pli­cat­ed by phar­ma­cy ben­e­fit man­agers — are un­rea­son­ably high and are not nec­es­sar­i­ly linked to the in­vest­ments in R&D. An­nu­al and some­times bian­nu­al hikes that of­ten ex­ceed the rate of in­fla­tion add an­oth­er lay­er of frus­tra­tion.

GoodRx, a com­pa­ny that tracks pre­scrip­tion drug prices in the Unit­ed States and of­fers dis­counts on med­ica­tions, has found that since 2014 (when it start­ed track­ing the da­ta) the pace of an­nu­al price hikes has in­creased, and the num­ber of drugs that are get­ting price up­grades has al­so be­come pro­nounced.

How­ev­er, as po­lit­i­cal scruti­ny in­to drug pric­ing in­ten­si­fied in re­cent years, a hand­ful of big drug­mak­ers pledged to keep their an­nu­al price hikes un­der 10% — and the gen­er­al spot­light on pric­ing has al­so be­gun to thaw the over­all mag­ni­tude of hikes.

This Jan­u­ary, over 100 drug­mak­ers raised the price for 619 brand­ed drugs by an av­er­age of 5.2%. In Jan­u­ary 2019, 486 brand­ed drugs saw in­creas­es by an av­er­age of 5.2%, while 580 brand­ed drugs in­creased by an av­er­age of 8% in Jan­u­ary 2018, ac­cord­ing to GoodRx da­ta. These num­bers should look dif­fer­ent when the to­tal num­ber of hikes over the rest of the year are ac­count­ed for.

Drug man­u­fac­tur­ers of­ten ar­gue that they raise list prices to ac­count for high­er re­bates that are ne­go­ti­at­ed by PBMs — and that net prices and what the pa­tient on av­er­age pays in cer­tain cas­es are in fact low­er.

“Re­bates are kind of hard to no­tice be­cause they’re kind of very hush-hush,” Tori Marsh, a GoodRx health in­sights an­a­lyst, not­ed in an in­ter­view with End­points News.

When list prices in­crease, that hike is passed on to in­sured pa­tients through co-pay­ments and pre­mi­ums, she said. “And so in­evitably, lat­er on down the line, they’re like­ly go­ing to be pay­ing more be­cause drug prices are just in­creas­ing — so they might not ex­pe­ri­ence it im­me­di­ate­ly at the phar­ma­cy but it will trick­le down.”

M&A: a crit­i­cal dri­ver for sus­tain­able top-line growth in health­care

2021 saw a record $600B in healthcare M&A activity. In 2022, there is an anticipated slowdown in activity, however, M&A prospects remain strong in the medium to long-term. What are future growth drivers for the healthcare sector? Where might we see innovations that drive M&A? RBC’s Andrew Callaway, Global Head, Healthcare Investment Banking discusses with Vito Sperduto, Global Co-Head, M&A.

Abortion-rights protesters regroup and protest following Supreme Court's decision to overturn Roe v. Wade. (AP Photo/Gemunu Amarasinghe)

Fol­low­ing SCO­TUS de­ci­sion to over­turn abor­tion pro­tec­tions, AG Gar­land says states can't ban the abor­tion pill

Following the Supreme Court’s historic decision on Friday to overturn Americans’ constitutional right to an abortion after almost 50 years, Attorney General Merrick Garland sought to somewhat reassure women that states will not be able to ban the prescription drug sometimes used for abortions.

Following the decision, the New England Journal of Medicine also published an editorial strongly condemning the reversal, saying it “serves American families poorly, putting their health, safety, finances, and futures at risk.”

AstraZeneca's new Evusheld direct to consumer campaign aims to reach more immunocompromised patients.

As­traZeneca de­buts first con­sumer cam­paign for its Covid-19 pro­phy­lac­tic Evusheld — and a first for EUA drugs

AstraZeneca’s first consumer ad for Evusheld is also a first for drugs that have been granted emergency use authorizations during the pandemic.

The first DTC ad for a medicine under emergency approval, the Evusheld campaign launching this week aims to raise awareness among immunocompromised patients — and spur more use.

Evusheld nabbed emergency authorization in December, however, despite millions of immunocompromised people looking for a solution and now more widespread availability of the drug.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.

Sanofi, GSK tout 72% Omi­cron ef­fi­ca­cy in PhI­II tri­al of next-gen, bi­va­lent shot — with an eye to year-end roll­out

Sometimes, being late can give you an advantage.

That’s what Sanofi and GSK are trying to say as the Big Pharma partners report positive results from a late-stage trial of their next-gen bivalent Covid-19 vaccine, which was designed to protect against both the original strain of the SARS-CoV-2 virus and the Beta variant. Specifically, against Omicron, they note, the vaccine delivered 72% efficacy in all adults and 93.2% in those previously infected.

Matt Kapusta, uniQure CEO

In trou­bled Hunt­ing­ton’s space, uniQure’s gene ther­a­py shows ear­ly promise

In randomized clinical trial data from a small number of patients, Dutch biotech uniQure shared that its gene therapy for Huntington’s disease seems to reduce the amount of the mutant protein responsible for the disease over the course of a year.

In seven patients with early-stage Huntington’s — four who got the treatment and three who got a placebo — mutant huntingtin protein levels in the cerebrospinal fluid decreased by an average of just over 50% in patients who got the gene therapy compared to around a 17% drop in patients who got the placebo after a year.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.

De­spite a slow start to the year for deals, PwC pre­dicts a flur­ry of ac­tiv­i­ty com­ing up

Despite whispers of a busy year for M&A, deal activity in the pharma space is actually down 30% on a semi-annualized basis, according to PwC’s latest report on deal activity. But don’t rule out larger deals in the second half of the year, the consultants said.

PwC pharmaceutical and life sciences consulting solutions leader Glenn Hunzinger expects to see Big Pharma companies picking up earlier stage companies to try and fill pipeline gaps ahead of a slew of big patent cliffs. Though a bear market continues to maul the biotech sector, Hunzinger said recent deals indicate that pharma companies are still paying above current trading prices.

Joe Wiley, Amryt Pharma CEO

Am­ryt Phar­ma sub­mits a for­mal dis­pute res­o­lu­tion to the FDA over re­ject­ed skin dis­ease drug

The story of Amryt Pharma’s candidate for the genetic skin condition epidermolysis bullosa, or EB, will soon enter another chapter.

After the Irish drugmaker’s candidate, dubbed Oleogel-S10 and marketed as Filsuvez, was handed a CRL earlier this year, the company announced in a press release that it plans to submit a formal dispute resolution request for the company’s NDA for Oleogel-S10.

John Leonard, Intellia CEO

In­tel­li­a's CRISPR pro­gram that ed­its genes di­rect­ly in pa­tients shows dura­bil­i­ty in AT­TR amy­loi­do­sis

The first in vivo CRISPR/Cas9 gene editing program has some new durability data showing sustained reduction of a toxic protein in ATTR amyloidosis at all four dose levels in a small 15-patient study.

Intellia Therapeutics presented the much-anticipated data for its Regeneron-collaborated NTLA-2001 Friday morning, adding to the initial Phase I results it first delivered almost a year ago to the day.

Sen. Thom Tillis (R-NC) (J. Scott Applewhite/AP Images)

Phar­ma-friend­ly sen­a­tor calls on FDA for a third time to show patent pro­tec­tions should­n't be blamed for high drug prices

North Carolina Republican Sen. Thom Tillis made a name for himself in the 2020 election cycle as the darling of the pharma industry, accepting hundreds of thousands in campaign contributions, even from the likes of Pfizer CEO Albert Bourla.

Those contributions have led Tillis to attempt to re-write patent laws in pharma’s favor, a move which failed to gain steam in 2019, and request for a third time since January that the FDA should help stop “the false narrative that patent protections are to blame for high drug prices.”